BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 27606939)

  • 1. Investigational drugs targeting cyclin-dependent kinases for the treatment of cancer: an update on recent findings (2013-2016).
    Di Giovanni C; Novellino E; Chilin A; Lavecchia A; Marzaro G
    Expert Opin Investig Drugs; 2016 Oct; 25(10):1215-30. PubMed ID: 27606939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
    Roskoski R
    Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).
    Malínková V; Vylíčil J; Kryštof V
    Expert Opin Ther Pat; 2015; 25(9):953-70. PubMed ID: 26161698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ATP-noncompetitive CDK inhibitors for cancer therapy: an overview.
    Abate AA; Pentimalli F; Esposito L; Giordano A
    Expert Opin Investig Drugs; 2013 Jul; 22(7):895-906. PubMed ID: 23735075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Cyclin-Dependent Kinases and Cell Cycle Progression in Human Cancers.
    Santo L; Siu KT; Raje N
    Semin Oncol; 2015 Dec; 42(6):788-800. PubMed ID: 26615126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting cyclin-dependent kinases in anti-neoplastic therapy.
    Bruyère C; Meijer L
    Curr Opin Cell Biol; 2013 Dec; 25(6):772-9. PubMed ID: 24011867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual action of the inhibitors of cyclin-dependent kinases: targeting of the cell-cycle progression and activation of wild-type p53 protein.
    Wesierska-Gadek J; Schmid G
    Expert Opin Investig Drugs; 2006 Jan; 15(1):23-38. PubMed ID: 16370931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An insight into the emerging role of cyclin-dependent kinase inhibitors as potential therapeutic agents for the treatment of advanced cancers.
    Chohan TA; Qayyum A; Rehman K; Tariq M; Akash MSH
    Biomed Pharmacother; 2018 Nov; 107():1326-1341. PubMed ID: 30257348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms.
    Senderowicz AM
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S61-73. PubMed ID: 12819936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological cyclin dependent kinase inhibitors: Implications for colorectal cancer.
    Balakrishnan A; Vyas A; Deshpande K; Vyas D
    World J Gastroenterol; 2016 Feb; 22(7):2159-64. PubMed ID: 26900281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer.
    Ding L; Cao J; Lin W; Chen H; Xiong X; Ao H; Yu M; Lin J; Cui Q
    Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32183020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcription-Associated Cyclin-Dependent Kinases as Targets and Biomarkers for Cancer Therapy.
    Chou J; Quigley DA; Robinson TM; Feng FY; Ashworth A
    Cancer Discov; 2020 Mar; 10(3):351-370. PubMed ID: 32071145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclin-dependent kinase inhibitors for the treatment of chronic lymphocytic leukemia.
    Blachly JS; Byrd JC; Grever M
    Semin Oncol; 2016 Apr; 43(2):265-73. PubMed ID: 27040705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclin-dependent kinase inhibition: an opportunity to target protein-protein interactions.
    Klein MA
    Adv Protein Chem Struct Biol; 2020; 121():115-141. PubMed ID: 32312419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticancer therapeutic strategies based on CDK inhibitors.
    Esposito L; Indovina P; Magnotti F; Conti D; Giordano A
    Curr Pharm Des; 2013; 19(30):5327-32. PubMed ID: 23394082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclin-dependent kinase inhibitors as anticancer drugs.
    Krystof V; Uldrijan S
    Curr Drug Targets; 2010 Mar; 11(3):291-302. PubMed ID: 20210754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitors of cyclin-dependent kinases as cancer therapeutics.
    Whittaker SR; Mallinger A; Workman P; Clarke PA
    Pharmacol Ther; 2017 May; 173():83-105. PubMed ID: 28174091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclin-dependent kinase inhibitors for the treatment of lung cancer.
    Qin A; Reddy HG; Weinberg FD; Kalemkerian GP
    Expert Opin Pharmacother; 2020 Jun; 21(8):941-952. PubMed ID: 32164461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The roles and therapeutic potential of cyclin-dependent kinases (CDKs) in sarcoma.
    Liao Y; Feng Y; Shen J; Hornicek FJ; Duan Z
    Cancer Metastasis Rev; 2016 Jun; 35(2):151-63. PubMed ID: 26669603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclin-Dependent Kinase 4 and 6 Inhibitors in Cell Cycle Dysregulation for Breast Cancer Treatment.
    Susanti NMP; Tjahjono DH
    Molecules; 2021 Jul; 26(15):. PubMed ID: 34361615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.